Buy Crispr
Amount
Latest price
$38.56
(£1.00 = $1.319)
Number of shares (est.)
0
Start investing today
Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.
Metrics
Market Cap
$3.329B
P/E ratio
-8.94
EPS
-$4.342
Beta
1.81
Dividend rate
N/A
Dividend yield
N/A
About
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
CEO
Dr. Samarth Kulkarni, Ph.D.
Employees
393
Sector
Health
Company HQ
ZUG, Switzerland
Website
News
3 Magnificent Stocks That Could Double or More by 2030
When the stock market is as turbulent as it is these days, it's easy to forget the times when things are decidedly more cheery. However, sell-offs present great opportunities to buy stocks with significant upside potential.
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Vertex Pharmaceuticals (VRTX -1.39%) is a great example of biotech success. The company has built a cystic fibrosis (CF) empire, bringing in billions of dollars in revenue annually, and now is even expanding into other promising billion-dollar opportunities.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
© 2025 Emma Technologies Ltd. All Rights Reserved.
Emma is registered and incorporated in England and Wales.
Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).
Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.
Emma Technologies Ltd is an Introducer Appointed Representative of Quint Group Limited, which is authorised and regulated by the Financial Conduct Authority (FRN 669450). Emma Technologies Ltd is not a lender. Emma Technologies Ltd introduces customers to Monevo Limited who is a licensed credit broker.
Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.
Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.
All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.
Resources: Cancel subscriptions, Cashback offers, Who charged me, Rent Reporting, Budgeting, Investment universe.
Featured cashback offers: Samsung, SimplyCook, NordVPN, Audible, M&S Homeware.